A Current Practice Study of Rituxan in Patient Receiving BEAM Chemotherapy and Autologous Blood Stem Cell Transplantation for High Risk Lymphoma or Hodgkin's Disease

Trial Profile

A Current Practice Study of Rituxan in Patient Receiving BEAM Chemotherapy and Autologous Blood Stem Cell Transplantation for High Risk Lymphoma or Hodgkin's Disease

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 May 2017

At a glance

  • Drugs Rituximab (Primary) ; Autologous stem cell therapy; Carmustine; Cytarabine; Etoposide; Melphalan
  • Indications Hodgkin's disease; Lymphoma
  • Focus Therapeutic Use
  • Acronyms Rituxan+BEAM
  • Most Recent Events

    • 25 Sep 2015 Planned End Date changed from 1 Oct 2018 to 1 Aug 2018 as reported by ClinicalTrials.gov reecord.
    • 29 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top